PROAbbvie Inc
stock281.12
+4.65 (+1.68%)
Price as of 13 Oct, 12:20 · Rate limit reached. Please try again in a minute.
Good Money Guide Pro Score
Strong
Strong investment profile
Technical Analysis
Short-Term Outlook
Neutral
2 bull · 2 bear · 1 neutral
Medium-Term Outlook
Bullish
4 bull · 0 bear · 0 neutral
Price above 50-day MA
Price above 200-day MA
Price above 12-day EMA
Price above 26-day EMA
Neutral momentum zone
MACD above signal line
%K below %D
Price near upper band — potential reversal
Volatility measure — informational only
Volume Indicators
On Balance Volume (OBV)
Volume Accumulation Distribution (VAD)
Market Statistics
Day Change
+4.65
Market Cap
449454440000
Exchange
NYSE
Sector
Health Care
Fundamentals
Rate limit reached. Please try again in a minute.
Analyst Forecast
Rate limit reached. Please try again in a minute.
Fundamental Analysis
Unable to load fundamental data
Learn about Abbvie Inc
What is Abbvie Inc?
AbbVie Inc. is a global research-based biopharmaceutical company that emerged from a spin-off of Abbott Laboratories in 2013. The company focuses on developing advanced therapies for complex diseases, with a portfolio covering areas like immunology, oncology, neuroscience, and eye care.
Is Abbvie Inc a good investment?
Investors often value AbbVie for its consistent dividend growth and strong pipeline of innovative drugs, though it faces risks related to patent expirations for key products and intense competition in the pharmaceutical industry. Performance can fluctuate based on regulatory decisions and drug trial outcomes, so please remember this information is for educational purposes and does not constitute financial advice.
How do you invest in Abbvie Inc?
You can invest in AbbVie by purchasing shares directly through a regulated online brokerage platform that provides access to the New York Stock Exchange. Alternatively, you can gain indirect exposure by investing in healthcare-focused ETFs or mutual funds that include ABBV as a constituent holding.
Educational content generated by AI — not financial advice.
Time & Sales
No trades yet.
News & Sentiment
Rate limit reached. Please try again in a minute.
Community Discussion
No posts yet for ABBV — be the first to start the discussion.
Point & Figure Analysis
OHLC
Signals
as of 08 Oct 2026Targets
Famous Investors Holding ABBV
Ken Fisher
9.50M sh · 0.7% of portfolio
$2.39B
NEW
Ken Griffin
3.17M sh · 0.1% of portfolio
$797.64M
NEW
Ken Griffin
1.99M sh · 0.1% of portfolio
$500.84M
NEW
Ken Griffin
1.40M sh · 0.0% of portfolio
$352.70M
NEW
Mario Gabelli
13.6K sh · 0.0% of portfolio
$3.42M
NEW
Ray Dalio
11.8K sh · 0.0% of portfolio
$2.96M
NEW
Source: SEC Form 13F, reporting period 30 Jun 2026. 45-day lag applies.